OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 466 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR SABCS 2021: New Research and Updates in Breast Cancer Treatment and... January 20, 2022 Mom Fighting Breast Cancer Says Her Haunted House Is Something To... October 30, 2019 The Frontline Oncology Workforce Unites to Reduce the Burden of Cancer... September 9, 2022 EMA Recommends Extension of Therapeutic Indications for Olaparib June 27, 2022 Load more HOT NEWS Prognostic Role of Plasmatic BRAF Allele Fraction for Survival in Patients... What to Know About Mastectomy With Flat Closure After a Breast... 10 Ways to Provide Support During Breast Cancer Awareness Month FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
